{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-000114","form_type":"8-K","ticker":"PROF","cik":"0001628808","company_name":"Profound Medical Corp.","filed_at":"2025-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.238241+00:00","generated_at":"2026-05-28T06:47:24.600133+00:00","sec_items":["2.02","8.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Profound Medical Q4 revenue up ~105-110% YoY; switches to US GAAP","bullets":["Preliminary Q4 2024 revenue $4.1-4.2M, YoY growth 105-110%, sequential growth 45-48%.","Preliminary FY2024 revenue $11.1-11.2M vs $7.2M in FY2023.","As of Jan 1, 2025, transitioning from IFRS to US GAAP; will file US domestic forms (10-K, 10-Q, 8-K).","TULSA procedure now reimbursed at Urology APC Level 7 across multiple treatment settings.","Company to present at JPM 2025 on Jan 16 at 11:15 a.m. PT."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-000114","json":"https://secwatch.observer/filing/0001171843-25-000114.json","markdown":"https://secwatch.observer/filing/0001171843-25-000114.md","text":"https://secwatch.observer/filing/0001171843-25-000114.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1628808/000117184325000114/0001171843-25-000114-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1628808/000117184325000114/f8k_010825.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T06:47:24.600133+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}